C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab, initially approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) [20], binds to the complement protein C5, thereby inhibiting its cleavage to C5a and C5b.